Jacob Borrajo
Chief Executive Officer at Amber Bio, Inc.
Profile
Jacob Borrajo is the founder of Coral Genomics, Inc. Mr. Borrajo is also the founder of Amber Bio, Inc.
Jacob Borrajo active positions
| Companies | Position | Start |
|---|---|---|
Amber Bio, Inc.
 Amber Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Amber Bio, Inc. is a biotechnology company based in an undisclosed location. The American company is focused on developing a first-of-its-kind RNA editing platform that can correct genetic mutations in a safe and reversible way. Amber Bio is pioneering new gene editing modalities using multi-kilobase RNA writing to reach previously undruggable diseases. Co-founders Jacob Borrajo and Basem Al-Shayeb received their Ph.D. at leading institutions for gene editing research: Broad Institute of MIT & Harvard and University of California. Jacob Borrajo has been the CEO since incorporation. | Chief Executive Officer | - |
Former positions of Jacob Borrajo
| Companies | Position | End |
|---|---|---|
Coral Genomics, Inc.
 Coral Genomics, Inc. Pharmaceuticals: MajorHealth Technology Coral Genomics, Inc. operates as a biotechnology company that optimizes drug development and deployment by utilizing genomic data from patients. The company was founded by Jacob Borrajo and Atray Dixit in 2018 and is headquartered in San Francisco, CA. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Coral Genomics, Inc.
Coral Genomics, Inc. Pharmaceuticals: MajorHealth Technology Coral Genomics, Inc. operates as a biotechnology company that optimizes drug development and deployment by utilizing genomic data from patients. The company was founded by Jacob Borrajo and Atray Dixit in 2018 and is headquartered in San Francisco, CA. | Health Technology |
Amber Bio, Inc.
Amber Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Amber Bio, Inc. is a biotechnology company based in an undisclosed location. The American company is focused on developing a first-of-its-kind RNA editing platform that can correct genetic mutations in a safe and reversible way. Amber Bio is pioneering new gene editing modalities using multi-kilobase RNA writing to reach previously undruggable diseases. Co-founders Jacob Borrajo and Basem Al-Shayeb received their Ph.D. at leading institutions for gene editing research: Broad Institute of MIT & Harvard and University of California. Jacob Borrajo has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Jacob Borrajo
